- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05028972
Slechthorendheid, strategieën en resultaten op VA-afdelingen voor spoedeisende hulp (HearVA-ED)
HearVA implementeren (I-HearVA)
HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff can implement this program and achieve similar results. The second part will give ED staff increasing levels of responsibility for screening Veterans for hearing difficulty and providing personal amplifiers when such difficulty is detected.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
HearVA is a randomized controlled trial to explore the utility and outcomes of providing point-of-care access to hearing-impaired Veterans, comparing an offer of personal amplifiers versus control in an environment where the clinical stakes are high. It addresses a knowledge gap about the utility of providing such hearing assistance during clinical encounters. The study measures whether providing personal amplifiers is acceptable to older patients, can improve hearing, enhance understanding of discharge instructions, and improve care transitions at discharge. If such a strategy is beneficial, this simple low-tech approach has great potential for implementation and wide dissemination. HearVA-ED has two phases - the first, which has been completed, established the feasibility and acceptability of research and procedures in the ED environment through a pilot efficacy study and the second phase will be to complete a larger more definitive efficacy study and a detailed implementation study resulting in a strategic approach that can be widely disseminated across all VA emergency departments throughout the United States. This second phase will use a mixed-methods, hybrid effectiveness-implementation design to implement and evaluate the hearing assistance intervention in six VA Emergency Department Sites (in different facilities across the country). Implementation will occur in four stages with variation in the starting sequence at each site: The first group of two VA emergency departments will initiate implementation with an efficacy trial; second group of two sites will initiate implementation with delivery and support of personal amplifiers after screening and randomization by a research assistant (Stage 1); the third group of two sites will initiate implementation with the entire implementation (Stage 2) and the presence of a research assistant to conduct discharge interviews; and all sites will progress from this sequence to Stage 3 - Sustainability - which is the full implementation without research assistant presence.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Joshua Chodosh, MD MSHS
- Telefoonnummer: 48491 (310) 478-3711
- E-mail: Joshua.Chodosh@va.gov
Studie Contact Back-up
- Naam: Lin T Tun
- Telefoonnummer: (646) 501-4132
- E-mail: lin.tun@va.gov
Studie Locaties
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045-7211
- Werving
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contact:
- Lauren Abbate, MD
- Telefoonnummer: 3177 303-399-8020
- E-mail: lauren.abbate@va.gov
-
-
New York
-
New York, New York, Verenigde Staten, 10010-5011
- Werving
- VA NY Harbor Healthcare System, New York, NY
-
Hoofdonderzoeker:
- Joshua Chodosh, MD MSHS
-
Contact:
- Olga Dotsenko
- Telefoonnummer: 3323 (212) 686-7500
- E-mail: olga.dotsenko@va.gov
-
Contact:
- Andrea M Aquines
- Telefoonnummer: (212) 686-7500
- E-mail: andrea.aquines@va.gov
-
Syracuse, New York, Verenigde Staten, 13210-2716
- Actief, niet wervend
- Syracuse VA Medical Center, Syracuse, NY
-
The Bronx, New York, Verenigde Staten, 10468
- Werving
- James J. Peters VA Medical Center, Bronx, NY
-
Contact:
- Ula Hwang, MD
- Telefoonnummer: 3816 718-584-9000
- E-mail: ula.hwang@va.gov
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27705-3875
- Werving
- Durham VA Medical Center, Durham, NC
-
Contact:
- Luna Ragsdale, MD
- E-mail: luna.ragsdale@va.gov
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75216-7167
- Werving
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Contact:
- Rohit Manaktala, MD
- E-mail: Rohit.Manaktala@va.gov
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- English speaking
- Emergency severity index criterion of 3 (medium), 4, or 5 (low acuity)
- Hearing Handicap Inventory-Screen greater than or equal to 10 or positive answer to a single-item screening question
- Capacity to consent to participate in research
Exclusion Criteria:
- Inability to consent to participate in research
- Emergency severity index criterion of 1-2 (high acuity)
- Hearing Handicap Inventory-Screen less than 10 and negative answer to single item screening question
- Inability to speak English
- Using cochlear implants
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intervention: Personal Amplifier
Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department |
The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
Andere namen:
|
|
Ander: Control: No Personal Amplifier
Consenting participants will be randomly assigned to the control group while receiving care in the emergency department |
The control group will not receive personal amplifiers while they receive care in the ED |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Emergency department (ED) 3-day Readmissions
Tijdsspanne: 3-5 days after initial ED stay
|
The Investigators will determine whether patients have had an ED revisit within three days through CPRS review as well as a brief follow-up phone call 3-5 days after ED discharge |
3-5 days after initial ED stay
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Emergency department (ED) 30-day Readmissions
Tijdsspanne: 30-35 days after initial ED stay
|
The Investigators will determine whether patients have had an ED revisit within 30 days through CPRS review as well as a brief follow-up phone call 30-35 days after ED discharge |
30-35 days after initial ED stay
|
|
Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During Emergency department (ED) Stay
Tijdsspanne: Duration of ED stay, average of 1 day
|
Participants will self-rate their quality of hearing, understanding, and communication using a six item questionnaire. Scored on a 10-point Likert scale (1 = do not agree at all; 10 = completely agree) the questions will be: When I talked to the doctors and nurses today ... (1) their voices were very clear; (2) I was able to hear the sounds that I wanted to hear; (3) noises did not cause a problem for my hearing; and (4) listening did not make me tired. Two additional statements will explicitly capture understanding: (5) I was able to understand what they said; and (6) I was able to understand without making an effort. Higher scores will indicate better communication and understanding with providers. |
Duration of ED stay, average of 1 day
|
|
Patient-Rated Quality of Post-Discharge Care
Tijdsspanne: At time of discharge from ED, average 1 day
|
Patient-rated quality of post-discharge care using a three-item subset of the Care Transition Measure (CTM). The questions are scored on a 1-4 scale (1= strongly disagree; 4 = strongly agree): (1) The ED staff considered my preferences and those of my family or caregiver in deciding what my healthcare needs were for discharge; (2) Leaving the ED, I have a good understanding of the things I am responsible for in managing my health; (3) Leaving the ED, I clearly understand the purpose for each of my medications. Higher scores will indicate better discharge preparation. |
At time of discharge from ED, average 1 day
|
|
Self-Reported Understanding of Discharge Instructions
Tijdsspanne: 3-5 days after initial ED stay
|
Investigators will gauge self-reported understanding of discharge instructions using semi-structured interview data compared to documented discharge data. |
3-5 days after initial ED stay
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Joshua Chodosh, MD MSHS, VA NY Harbor Healthcare System, New York, NY
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IIR 17-068-1
- HX002421 (Ander subsidie-/financieringsnummer: VA HSR&D)
- 5I01HX002421-08 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .